Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

t(3;17)(q26;q12-21) TBL1XR1/RARA

Written2017-03Adriana Zamecnikova
Kuwait Cancer control Center, Department of Hematology, Kuwait; annadria@yahoo.com

Abstract In classic APL (acute promyelocytic leukemia), the central leukemia-initiating event is the fusion between the promyelocytic leukemia (PML) and the retinoic acid receptor alpha (RARA) gene, that arise as a result of t(15;17)(q22;q21) chromosomal translocation. In variant forms of APL, RARA gene have other translocation partners than PML resulting in various molecular characteristics and sensitivities to all-trans-retinoic acid (ATRA) therapy. The variant t(3;17)(q26;q21) translocation, in which RARA is fused to TBL1XR1 (transducin beta like 1 X-linked receptor 1, TBLR1) is a rare anomaly, observed only in sporadic cases.

Keywords Chromosome 3; chromosome 17; acute promyelocytic leukemia; retinoic acid receptor alpha; transducin beta like 1 X-linked receptor 1; RARA; TBL1XR1; TBL1XR1/RARA; fusion gene.

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424
ICD-Morpho 9866/3 Acute promyelocytic leukaemia with t(15;17)(q22;q12); PML-RARA
Atlas_Id 1602

Clinics and Pathology

Disease Acute promyelocytic leukemia (APL; FAB type M3)
Epidemiology 4 cases to date, 3 male and 1 female patients; ages at diagnosis was documented in 2 cases: 27 and 63 years (Macedo et al., 2005; Chen et al., 2014).
Clinics In one patient, data were available: bone marrow cells revealed hypercellularity with 83% hypergranular promyelocytes lacking Auer rods. Immunophenotyping analysis by flow cytometry was positive for myeloperoxidase, CD13, CD9 with partially expressed CD117, CD15, CD33, and CD64; CD34 and HLA-DR were negative (Chen et al., 2014).
Prognosis The one patient well described in Chenn et al., 2014 (63-year-old male patient) received induction therapy with ATRA, cytarabine, and mitoxantrone but failed to achieve complete remission (58% promyelocytes on day 32). Therapy with ATRA should be suspended on day 24 because of severe pulmonary infection. He was subsequently treated with arsenic trioxide and chemotherapy resulting in complete remission, but 10 months after diagnosis he relapsed with 81% of promyelocytes in bone marrow and died 1 month later (Chen et al., 2014). The female patient reported by Chen et al., 2014 was initially treated with ATRA and daunorubicin and achieved CR on day 36. However, in addition to the t(3;17)(q21;q25) TBL1XR1/RARA, a t(15;17)(q22;q12) PML/RARA transcript was also detected in this patient. In Machedo et al., 2005, the rearrangement t(3;17)(q26.3;q12) was accompanied with a poor outcome. Due to the limited data available regarding patient outcomes, the efficiency of ATRA on APL patients with TBLR1/RARA is unclear.

Cytogenetics

Cytogenetics Morphological Variable breakpoints on 3q and 17q, described as: t(3;17)(q26;q21), t(3;17)(q27;q22), t(3;17)(q21;q25) (Chen et al., 2014) (Author's note: the latter may be t(3;17)(q25;q21) ?) and as a t(3;17)(q26;q12) in a patient with unknown gene involved at 3q26 (Macedo et al., 2005).
Additional anomalies Part of complex karyotypes in all the 4 patients; recurrent abnormalities were: del(6)q), -7, del(7q) and in 1 patient t(15;17)(q22;q12) with PML/RARA fusion as above mentioned (Chen et al., 2014).

Genes involved and Proteins

Gene Name TBL1XR1
Location 3q26.32
Dna / Rna Approximately 200 kb of genomic DNA, containing 18 exons; member of the WD40 repeat-containing gene family and shares sequence similarity with transducin (beta)-like 1X-linked (TBL1X).
Protein 514 amino acids; contains lissencephaly type-1-like homology motif (LisH domain) in its N-terminal region, F-box-like domain, and 8 WD-40 repeats in its C-terminal region; an integral subunit of the NCOR1 (NCoR, nuclear receptor corepressor) and NCOR2 (SMRT, silencing mediator of retinoic acid and thyroid hormone receptors) repressor complexes that interact with nuclear receptors and repress transcription; required for transcriptional activation by a variety of transcription factors (Li et al., 2014).
Germinal mutations Heterozygous missense mutation of TBL1XR1 is associated with autosomal dominant Pierpont syndrome; deletions and mutations in this gene have been implicated in autism spectrum disorders and it is suggested that TBL1XR1 haploinsufficiency may be a cause of intellectual disability with dysmorphism (Heinen et al., 2016).
Somatic mutations TBL1XR1 mutations and recurrent translocations involving this gene have been observed in lymphatic malignancies, including diffuse large B-cell lymphoma, primary central nervous system lymphomas, acute lymphoblastic leukaemia and Sézary syndrome (Heinen et al., 2016).
Gene Name RARA
Location 17q21.2
Protein Nuclear retinoic acid receptor, implicated in regulation of development, differentiation, apoptosis, granulopoeisis, and transcription.
Retinoic acid receptor alpha belongs to the nuclear hormone receptor family composed of a modulating N-terminal domain, a nuclear receptor DNA-binding domain and a C-terminal ligand-binding domain. RARA can be combined with retinoid X receptor alpha to bind the retinoic acid responsive element composed of tandem 5'-AGGTCA-3' sites; mediates retinoic acid-induced granulopoiesis and regulates transcription in a ligand-dependent manner in various biological processes.

Result of the chromosomal anomaly

Hybrid gene
Description 5'-TBLR1-3' RARA
Transcript In-frame fusion transcript; TBLR1 exon 5 is fused to exon 3 of RARA
  
Fusion Protein
 
  Schematic representation of TBLR1, RARA and TBLR1/RARA proteins. Abbreviations: LisH (lissencephaly type-1-like homology motif); DBD; DNA-binding domain; (LBD), ligand-binding domain (Adopted from Chen et al., 2014).
Description Predicted to encode a 545 amino acids (aa) fusion protein, containing a LisH domain (6-32 aa) in the TBLR1 portion and a DNA-binding domain (DBD; 166-250 aa) and a ligand-binding domain (LBD; 270-500 aa) in the RARA portion (B through F domains of RARA) (Chen et al., 2014; Heinen et al., 2016).
Oncogenesis The common feature of RARA fusion proteins is the ability to self-associate, forming homodimers. The TBL1XR1/RARA fusion protein is predominantly localized in the nucleus and self-associate into homodimers through its LisH domain and associate with retinoid X receptor alpha into heterodimers. The multimerization of the chimeric protein may be a key factor in interfering with normal signaling leading to diminished transcriptional activity.
  

To be noted

Additional cases are needed to delineate the epidemiology of this rare entity:
you are welcome to submit a paper to our new Case Report section.

Bibliography

TBLR1 fuses to retinoid acid receptor ? in a variant t(3;17)(q26;q21) translocation of acute promyelocytic leukemia.
Chen Y, Li S, Zhou C, Li C, Ru K, Rao Q, Xing H, Tian Z, Tang K, Mi Y, Wang B, Wang M, Wang J.
Blood 2014 Aug 7;124(6):936-45.
PMID 24782508
 
A specific mutation in TBL1XR1 causes Pierpont syndrome.
Heinen CA, Jongejan A, Watson PJ, Redeker B, Boelen A, Boudzovitch-Surovtseva O, Forzano F, Hordijk R, Kelley R, Olney AH, Pierpont ME, Schaefer GB, Stewart F, van Trotsenburg AS, Fliers E, Schwabe JW, Hennekam RC.
J Med Genet 2016 May;53(5):330-7.
PMID 26769062
 
TBL1XR1 in physiological and pathological states.
Li JY, Daniels G, Wang J, Zhang X.
Am J Clin Exp Urol 2015 Apr 25;3(1):13-23. eCollection 2015.
PMID 26069883
 
New rearrangement t(3;17)(q26.3;q12) in an AML patient with a poor outcome.
Macedo SML, Land M, Heller A, Abdelhay E, do Socorro Pombo-de-Oliveira M, Ribeiro R, Alves G, Lerner D, Liehr T.
Oncol Rep 2005 Sep;14(3):663-6.
PMID 16077971
 

Citation

This paper should be referenced as such :
Zamecnikova A
t(3;17)(q26;q12-21) TBL1XR1/RARA;
Atlas Genet Cytogenet Oncol Haematol. in press
On line version : http://AtlasGeneticsOncology.org/Anomalies/t0317q26q21ID1602.html


Translocations implicated (Data extracted from papers in the Atlas)

 t(3;17)(q26;q21) TBL1XR1/RARA

External links

Mitelman databaset(3;17)(q26;q21) [Case List]    t(3;17)(q26;q21) [Association List] Mitelman database (CGAP - NCBI)
arrayMapMorph ( 9866/3) - arrayMap (UZH-SIB Zurich)  [auto + random 100 samples .. if exist ]   [tabulated segments]
 
 
Disease databaset(3;17)(q26;q12-21) TBL1XR1/RARA
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Sat Apr 22 09:42:33 CEST 2017


Home   Genes   Leukemias   Solid Tumours   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.